Asiapharm.com.my2

-Chinese Journal of Internal Medicine, June 1998, 37(6):400- Comparison of the Effects of Xuezhikang and Simvastatin on Lipid
Profile Modification in Patients with Hypercholesterolemia
(Internal Medicine Department of Jiamusi Central Hospital) Chinese Journal of Internal Medicine, 1998, Vol 37, No. 6 ABSTRACT
[Objective]: To study the effect of Xuezhikang on lipid profile modification in patients with hypercholesterolesmia and to compare it with Simvastatin. Methods 28 patients
with hypercholesterolesmia were randomly divided into a treatment group(n=15, Xuezhikang 1.2g/d qn, P.O) and a control group (n = 13, Simvastatin 10 mg/d qn, P.O). Blood samples were taken from forearm vein (fasting for 12 h) before and 4 weeks, 8 weeks after the treatement. Serum lipid profile was determined enzymatically and turbimetrically. Results (1) The effects Xuezhikang in lowering serum total cholesterol
(TC) and low density lipoprotein cholestrol (LDL-C) levels were the same as Simvastatin; the concentrations of TC and LDL-C decreased by 20.7% and 28.2% in Xuezhikang group (P < 0.001, < 0.01) respectively. (2) Xuezhikang decreased serum triglyceride (TG) levels by 17.4 % (P < 0.05) after 4-week treatment, but the decreased serum triglyceride (TG) levels by 17.4% (P < 0.05) after 4-week treatment, but the effect of Simvastatin lowering TG was not statistically significant. (3) Although concentrations of high density lipoprotein cholestrol (HDL-C) was not changed after 4-week treatment, apolipoprotein A1 (ApoA1) levels elevated by 12.7% and 13.6% into the two groups respectively; apolipoprotein B (ApoB) levels lowered by about 8% (P < 0.05) in both groups. It is interesting to note that lipoprotein(a) levels decreased by 31.3% and 27.8% (P < 0.05) in both Xuezhikang and Simvastatin groups after 8-week treatment. (4) Differences of the effects of both medicines on lipid serum profile at the end of 4- week and 8 week were not significant, through further lowering of the concentration of Lp(a) was noted in Xuezhikang group after 8 weeks as compared with 4 weeks. Conclusion Xuezhikang could markedly decrease TC and LDL-C concentrations of
patients with hypercholesterolemia and the effects of Xuezhikang were the same as those of Simvastatin. TG lowering effects of Xuezhikang were superior to that of [Key words]: Hypercholesterolemia, Simvastatin, Xuezhikang
INTRODUCTION
The treatment of hypercholesterolemia plays an important role in primary and secondary prevention and cure of coronary heart disease. Clinical studies indicate that, as a major lipid lowering medicine mainly containing HMG-CoA reducatase inhibitor, Xuezhikang can effectively reduce serum TC, TG, LDL-C levels and increase HDL-C level of hyperlipoidemia patients. In this study, Simvastatin was selected in the control group in order to compare lipid effects of the two medicine. PATIENTS AND METHODS
28 hypercholesterolemia patients who were not treated by other medicines were chosen (TC > 6.0 mmol/L or associated with TG > 2.26 mmol/L and patients with liver, renal or thyroid diseases were excluded) as subjects. They ceased administrating of other lipid lowering medicines for 4 weeks with the serum testing indexes still higher than then the above standards. These patients were divided into two groups randomly. One was 15- case Xuezhikang groups with 10 men and 5 women, aging 60 ± 10 years old and the body weight index (BWI) 24.7 ± 2.1. Among them, 9 cases were accompanied with hypertension and coronary disease. Another was the 13-case Simvastatin group with 8 men and 5 women, aging 54 ± 10 years old and BWI 24.8 ± 2.9. Among lipid levels of the two groups were basically the same. See Table 1. Drug Administration and Examinations Patients in Xuezhikang group took 1.2g draught Xuezhikang group took 1.2g draught Xuezhikang in the evening (Xuezhikang capsule is provided by WBL Peking University Biotech Limited Company, product approval number 951002). Whereas subjects in Simvastatin after dinner (The commercial name Simvastatin is called Zocor, product of Merck Sharp & Dohme China Limited Company). Forearm venous blood samples were taken on 12h-fasting patients after 4-week and 8- week treatment. Serum samples were stored under -50°C. All samples were tested once within 4 months. Before and after 8-week treatment, BUN, creatinine, ALT, creatinekinase and GLU were tested. During the treatment, patients basically kept their dietary habit and lifestyle unchanged. And subjects with hypertension or coronary disease could continue their administration of medicines as long as they did not impose Enzyme agent method was employed to determine the concentration of TC, TG, and HDL-C (after magnesium phosphotungstun precipation). The concentration of LDL-C was deprived from the formula: LDL-C = TC - HDL-C - TG x 0.46. Histoimmununological method was used to test ApoA1 and ApoB and ELISA method for LP(a) concentration. t-test was adopted in statistical analysis. There were no particular side-effects after 4-week and 8-week treatment of Xuezhikang or Simvastatin. There were also no significant changes of BUN, myoanhydride, ALT, After 4-week and 8-week treatment, Xuezhikang reduced serum TC by 20.7% and 22.3% respectively and Simvastatin reduced serum TC by 22.5% and 22% respectively with P < 0.001 indicating same serum TC reduction functions of both medicines. Xuezhikang also peformed similar to Simvastatin in terms of LDL-C reduction. LDL-C lecel decreased by 28.2% and 30% respectiely in Xuezhikang group (P < 0.1). In addition, Xuezhikang significantly decreased TG by 17.4% after 4-weeks treatment and 18.8% after 8 weeks treatment (P< 0.05) whereas Simvastatin produced no statistical differences in TG reduction. Therefore, the reduction level of TC and LDL-C by Xuezhikang and Simvastatin was more significant than TG reduction. (Table I) It was aslo showed in the study: 4 weeks and 8 weeks after treatment by Xuezhikang or Simvastatin, through no obvious change occurred in HDL-C level, ApoA1 concentration did increase by 12.7% and 11.9% in Xuezhikang group and 13.6% and 18.2% respectively in Simvastatin group with both P < 0.01. Apob level obviously decreased by about 8%in both groups. In addition, Xuezhikang reduced LP(a) by 31.3% (P < 0.01) and Simvastatin lowered Lp(a) level by 27.8% (P < 0.05, Table II). Table I. Comparison of Lipid Levels between the Two Groups(mmol/L , X ± s) Hyperlipoidemia
6.64±0.88 2.82±0.58 1.44±0.19 3.90±0.95 1.34±0.14 1.15±0.10 0.16±0.07 6.71±0.59 2.23±0.66 1.41±0.15 4.20±0.73 1.32±0.12 1.19±0.06 0.18±0.07 Table II. Comparison of Xuezhikang and Simvastatin on Lipid Modification for Hypercholesterolemia Patients Before Treatment
After Treatment
After Treatment
Note: Compared with that of before treatment, *P < 0.05, *P < 0.01. *P < 0.001 The findings also indicated: apart from further reduction of Lp(a) level by 8-weeks Simvastatin treatment, lipid regulation effects of both medicines after 8-weeks treatment had no significant differences compared with that of after 4 weeks treatment.
DISCUSSION
The findings proved that the administration of 1.2g/d Xuezhikang could dramatically reduce serum TC and LDL-C levels and the reduction margin was the same as that of Simvastatin. Past studies in China showed that the administration of 1.2g/d Xuezhikang could decrease serum TC and LDL-C by 22% and 30% respectively. The fact that Xuezhikang performs better in decreasing TG level is closely related to unsaturated fatty acids in Xuezhikang. It is known that un saturated fatty acids can distinctly decrease serum TG and very low-density lipoprotein. It may have something to do with averagely higher TG level of Xuezhikang group than that of Simvastatin group. Some other study illustrates that the higher the TG concentration before treatment, the more significant Xuezhikang could reduce TG level. Past domestic medical studies on Xuezhikang showed the curative effect of Xuezhikang on TG reduction is better than on TC reduction. The findings of this study were just on the contrary. The different type of patients selected in the study possibly accounted for this phenomenon. The subjects in this study were only type IIa nd IIb hypercholesterolemia patients. And no HDL-C elevation was observed on both Xuezhikang and Simvastatin treated groups as the sample may be too small. It was interesting to note that both Xuezhikang and Simvastatin could decrease the In conclusion, Xuezhikang has nearly the same functions in reducing the concentrations of serum TC and LDL-C compared with Simvastatin, but performs better to decrease TG
REFERENCES
1 . Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EngI Med, 1995, 333:1301-1307 2. The Scandinavian Simvastatin survival study group. Randomised trial of cholestrol lowering in 4, 444 patients with coronary heart disease: the Scandinavian Simvastatin survival study(4S). Lancet, 1994, 344:1383-1389. 3. The MAAS investigators. Effect of Simvastatin on coronary atheroma: the multicenter anti-atheroma study(MAAS). Lancet, 1994, 344:633-638 4. Lu zongliang, Xu Chen, Kou Wenrong. Clinical observatoions of the curative effect of different dosage of Xuezhikang on primary hyperlipoidemia, Chinese New Drugs Journal, 1997,5:354357. 5. Wang Junxian, Sun Meizhe, Lu zongliang, et al. Clinical study of Xuezhikang capsule on hyperlipoidemia , Chinese Journal of Experimental Traditional Medical Formulae, 1995, 1:1-5. 6. Su Meizhe, Wang Xiaohong, Li Yan, et al. Clinical observation of Xuezhikang capsule on hyperlipoidemia, Traditional Chinese Drug Research & Clinical Pharmocology, 1995, 6:13-16 2008 Asiapharm Biotech Pte Ltd. All rights reserved. Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. You should carefully read all product packaging. If you have or suspect you have a medical problem, promptly contact your professional healthcare provider. Statements and information regarding dietary supplements have not been evaluated or approved by the U.S. Food and Drug Administration. Please consult your healthcare provider before beginning any course of supplementation or treatment.

Source: http://asiapharm.com.my/lipascor_studies/Comparison-of-the-Effects-of-Xuezhikang.pdf